GSK plc (LON:GSK) Given Average Rating of "Moderate Buy" by Brokerages

Shares of GSK plc (LON:GSK - Get Free Report) have been given an average recommendation of "Moderate Buy" by the seven analysts that are presently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is GBX 1,805.83 ($23.45).

Separately, JPMorgan Chase & Co. reaffirmed an "underweight" rating on shares of GSK in a research report on Friday, March 28th.

GSK Stock Performance

Shares of GSK stock traded down GBX 35.50 ($0.46) during trading on Friday, hitting GBX 1,433.50 ($18.61). 7,824,058 shares of the stock were exchanged, compared to its average volume of 17,908,732. GSK has a 1-year low of GBX 1,282.50 ($16.65) and a 1-year high of GBX 1,823.50 ($23.68). The stock has a market capitalization of £58.17 billion, a price-to-earnings ratio of 23.16, a price-to-earnings-growth ratio of 1.24 and a beta of 0.31. The company has a fifty day moving average price of GBX 1,461.96 and a 200-day moving average price of GBX 1,428.59. The company has a current ratio of 0.81, a quick ratio of 0.73 and a debt-to-equity ratio of 114.64.

GSK (LON:GSK - Get Free Report) last released its quarterly earnings data on Wednesday, February 5th. The company reported GBX 23.20 ($0.30) earnings per share (EPS) for the quarter. GSK had a return on equity of 18.08% and a net margin of 8.02%. As a group, equities analysts predict that GSK will post 175.980975 EPS for the current fiscal year.

Insider Activity

In related news, insider Emma Walmsley sold 120,653 shares of the stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of GBX 1,453 ($18.87), for a total transaction of £1,753,088.09 ($2,276,442.14). Also, insider Wendy Becker acquired 536 shares of the company's stock in a transaction on Thursday, March 20th. The stock was bought at an average cost of GBX 1,515 ($19.67) per share, with a total value of £8,120.40 ($10,544.60). 1.61% of the stock is currently owned by company insiders.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.